Burning Rock Biotech Ltd (BNR)

$0.85

Market is closed - opens 7 PM, 29 Apr 2024

Insights on Burning Rock Biotech Ltd

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 146.26M → 121.08M (in $), with an average decrease of 8.9% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -174.98M → -162.21M (in $), with an average increase of 7.9% per quarter

  • Vs IQV

    In the last 1 year, Iqvia Holdings Inc. has given 23.2% return, outperforming this stock by 94.3%

  • Vs TMO

    In the last 3 years, Thermo Fisher Scientific, Inc. has given 0.2% return, outperforming this stock by 97.3%

Performance

  • $0.79
    $0.88
    $0.85
    downward going graph

    7.53%

    Downside

    Day's Volatility :10.67%

    Upside

    3.4%

    downward going graph
  • $0.57
    $3.25
    $0.85
    downward going graph

    32.68%

    Downside

    52 Weeks Volatility :82.39%

    Upside

    73.85%

    downward going graph

Returns

PeriodBurning Rock Biotech LtdSector (Health Care)Index (Russel 2000)
3 Months
-0.81%
0.5%
0.0%
6 Months
-20.56%
11.7%
0.0%
1 Year
-71.09%
6.2%
2.2%
3 Years
-97.14%
13.5%
-23.0%

Highlights

Market Capitalization
84.3M
Book Value
$7.5
Earnings Per Share (EPS)
-0.96
Wall Street Target Price
3.95
Profit Margin
-121.63%
Operating Margin TTM
-137.36%
Return On Assets TTM
-31.84%
Return On Equity TTM
-67.85%
Revenue TTM
537.4M
Revenue Per Share TTM
5.25
Quarterly Revenue Growth YOY
-14.899999999999999%
Gross Profit TTM
380.0M
EBITDA
-548.6M
Diluted Eps TTM
-0.96
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    80%Buy
    20%Hold
    0
    0%Sell
Based on 5 Wall street analysts offering stock ratings for Burning Rock Biotech Ltd(by analysts ranked 0 to 5 stars)
Based on 5 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
4
4
5
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 364.71%

Current $0.85
Target $3.95

Company Financials

FY18Y/Y Change
Revenue
30.4M
↑ 87.89%
Net Income
-25.8M
↑ 35.21%
Net Profit Margin
-84.98%
↑ 33.11%
FY19Y/Y Change
Revenue
54.6M
↑ 82.74%
Net Income
-24.1M
↓ 5.16%
Net Profit Margin
-44.1%
↑ 40.88%
FY20Y/Y Change
Revenue
65.9M
↑ 12.64%
Net Income
-57.3M
↑ 122.0%
Net Profit Margin
-86.93%
↓ 42.83%
FY21Y/Y Change
Revenue
79.7M
↑ 18.13%
Net Income
-125.0M
↑ 113.19%
Net Profit Margin
-156.87%
↓ 69.94%
FY22Y/Y Change
Revenue
81.7M
↑ 10.9%
Net Income
-140.8M
↑ 21.91%
Net Profit Margin
-172.44%
↓ 15.57%
FY23Y/Y Change
Revenue
537.4M
↓ 4.58%
Net Income
-653.7M
↓ 32.69%
Net Profit Margin
-121.63%
↑ 50.81%
Q3 FY22Q/Q Change
Revenue
21.7M
↑ 0.0%
Net Income
-31.8M
↑ 0.0%
Net Profit Margin
-146.35%
↑ 0.0%
Q4 FY22Q/Q Change
Revenue
20.7M
↓ 7.83%
Net Income
-26.9M
↓ 18.14%
Net Profit Margin
-129.99%
↑ 16.36%
Q1 FY23Q/Q Change
Revenue
20.7M
↓ 0.2%
Net Income
-31.5M
↑ 16.72%
Net Profit Margin
-152.02%
↓ 22.03%
Q2 FY23Q/Q Change
Revenue
20.2M
↑ 2.83%
Net Income
-18.1M
↓ 39.3%
Net Profit Margin
-89.73%
↑ 62.29%
Q3 FY23Q/Q Change
Revenue
127.6M
↓ 12.79%
Net Income
-175.0M
↑ 33.33%
Net Profit Margin
-137.17%
↓ 47.44%
Q4 FY23Q/Q Change
Revenue
121.1M
↓ 5.08%
Net Income
-162.2M
↓ 7.3%
Net Profit Margin
-133.97%
↑ 3.2%
FY18Y/Y Change
Total Assets
54.2M
-
Total Liabilities
141.9M
-
FY19Y/Y Change
Total Assets
121.3M
↑ 127.43%
Total Liabilities
248.9M
↑ 78.16%
FY20Y/Y Change
Total Assets
408.3M
↑ 214.2%
Total Liabilities
37.1M
↓ 86.08%
FY21Y/Y Change
Total Assets
357.6M
↓ 14.44%
Total Liabilities
68.0M
↑ 79.02%
FY22Y/Y Change
Total Assets
230.2M
↓ 30.33%
Total Liabilities
62.2M
↓ 0.96%
FY23Y/Y Change
Total Assets
1.0B
↓ 34.49%
Total Liabilities
271.6M
↓ 36.71%
Q3 FY22Q/Q Change
Total Assets
243.0M
↑ 0.0%
Total Liabilities
60.7M
↑ 0.0%
Q4 FY22Q/Q Change
Total Assets
205.5M
↓ 18.13%
Total Liabilities
53.9M
↓ 14.0%
Q1 FY23Q/Q Change
Total Assets
231.1M
↑ 12.0%
Total Liabilities
62.5M
↑ 15.42%
Q2 FY23Q/Q Change
Total Assets
183.5M
↓ 16.17%
Total Liabilities
50.1M
↓ 15.37%
Q3 FY23Q/Q Change
Total Assets
1.2B
↓ 12.33%
Total Liabilities
303.7M
↓ 16.36%
Q4 FY23Q/Q Change
Total Assets
1.0B
↓ 10.86%
Total Liabilities
271.6M
↓ 10.59%
FY18Y/Y Change
Operating Cash Flow
-21.6M
↑ 11.28%
Investing Cash Flow
15.4M
↓ 155.52%
Financing Cash Flow
12.1M
↓ 76.45%
FY19Y/Y Change
Operating Cash Flow
-32.6M
↑ 53.27%
Investing Cash Flow
-49.6M
↓ 426.76%
Financing Cash Flow
81.8M
↑ 585.59%
FY20Y/Y Change
Operating Cash Flow
-11.3M
↓ 67.75%
Investing Cash Flow
-16.8M
↓ 68.47%
Financing Cash Flow
332.1M
↑ 278.8%
FY21Y/Y Change
Operating Cash Flow
-75.0M
↑ 549.8%
Investing Cash Flow
12.8M
↓ 174.74%
Financing Cash Flow
-8.3M
↓ 102.44%
FY22Y/Y Change
Operating Cash Flow
-66.2M
↓ 4.41%
Investing Cash Flow
-1.1M
↓ 109.13%
Financing Cash Flow
-12.5M
↑ 63.02%
Q3 FY22Q/Q Change
Operating Cash Flow
-19.0M
↑ 0.0%
Investing Cash Flow
-2.8M
↓ 165.57%
Financing Cash Flow
-374.9K
↑ 0.0%
Q4 FY22Q/Q Change
Operating Cash Flow
-16.4M
↓ 16.48%
Investing Cash Flow
-729.8K
↓ 75.02%
Financing Cash Flow
-4.6K
↓ 98.8%
Q1 FY23Q/Q Change
Operating Cash Flow
-9.9M
↓ 40.16%
Investing Cash Flow
-590.8K
↓ 19.35%
Financing Cash Flow
-1.5M
↑ 31381.25%
Q2 FY23Q/Q Change
Operating Cash Flow
-10.9M
↑ 16.98%
Investing Cash Flow
-403.7K
↓ 27.86%
Financing Cash Flow
-138.3K
↓ 90.04%

Technicals Summary

Sell

Neutral

Buy

Burning Rock Biotech Ltd is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Burning Rock Biotech Ltd
Burning Rock Biotech Ltd
21.44%
-20.56%
-71.09%
-97.14%
-96.55%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
-7.79%
23.1%
1.62%
-12.39%
110.45%
Agilent Technologies Inc.
Agilent Technologies Inc.
-5.57%
30.74%
2.44%
-0.71%
76.14%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
0.51%
29.89%
7.24%
15.73%
109.26%
Danaher Corp.
Danaher Corp.
-1.07%
26.91%
5.73%
-4.77%
87.73%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
-5.55%
26.87%
23.16%
0.24%
68.7%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Burning Rock Biotech Ltd
Burning Rock Biotech Ltd
NA
NA
NA
0.0
-0.68
-0.32
NA
7.5
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
49.03
49.03
4.75
11.13
0.81
0.23
NA
17.88
Agilent Technologies Inc.
Agilent Technologies Inc.
32.89
32.89
2.7
5.5
0.21
0.08
0.01
21.12
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
37.35
37.35
2.81
21.53
0.13
0.05
0.0
120.87
Danaher Corp.
Danaher Corp.
45.86
45.86
3.13
7.63
0.08
0.04
0.0
72.16
Iqvia Holdings Inc.
Iqvia Holdings Inc.
32.05
32.05
1.33
11.11
0.23
0.05
NA
33.67
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Burning Rock Biotech Ltd
Burning Rock Biotech Ltd
Buy
$84.3M
-96.55%
NA
-121.63%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
Buy
$41.1B
110.45%
49.03
23.08%
Agilent Technologies Inc.
Agilent Technologies Inc.
Buy
$40.8B
76.14%
32.89
18.35%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
Buy
$220.4B
109.26%
37.35
13.99%
Danaher Corp.
Danaher Corp.
Buy
$185.5B
87.73%
45.86
18.55%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
Buy
$42.6B
68.7%
32.05
9.06%

Institutional Holdings

  • Kynam Capital Management, LP

    8.47%

  • Massachusetts Financial Services Company

    3.94%

  • Fidelity International Ltd

    2.74%

  • Millennium Management LLC

    1.70%

  • Nikko Asset Management Americas Inc

    0.65%

  • Sumitomo Mitsui Trust Holdings Inc

    0.58%

Corporate Announcements

  • Burning Rock Biotech Ltd Earnings

    Burning Rock Biotech Ltd’s price-to-earnings ratio stands at None

    Read More

Company Information

Headquartered in China and founded in 2014, Burning Rock, whose mission is to Guard Life via Science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology.

Organization
Burning Rock Biotech Ltd
Employees
0
CEO
Mr. Yusheng Han
Industry
Health Services

Discover More

FAQs